Accolade (NASDAQ:ACCD) Shares Gap Down Following Analyst Downgrade

Shares of Accolade, Inc. (NASDAQ:ACCD) gapped down before the market opened on Friday after Morgan Stanley lowered their price target on the stock from $13.00 to $12.00. The stock had previously closed at $9.19, but opened at $7.87. Morgan Stanley currently has an equal weight rating on the stock. Accolade shares last traded at $8.19, with a volume of 200,076 shares changing hands.

Several other research firms also recently commented on ACCD. Raymond James boosted their target price on Accolade from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Tuesday, January 9th. SVB Leerink assumed coverage on shares of Accolade in a research report on Monday, February 26th. They set an “outperform” rating and a $16.00 price objective on the stock. Barclays decreased their target price on shares of Accolade from $13.00 to $11.00 and set an “equal weight” rating for the company in a report on Friday. Needham & Company LLC cut their price target on shares of Accolade from $17.00 to $13.00 and set a “buy” rating on the stock in a report on Friday. Finally, Canaccord Genuity Group reduced their price target on shares of Accolade from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $14.80.

Institutional Investors Weigh In On Accolade

Hedge funds have recently added to or reduced their stakes in the stock. ARK Investment Management LLC increased its position in Accolade by 12.6% during the fourth quarter. ARK Investment Management LLC now owns 6,805,208 shares of the company’s stock valued at $81,731,000 after acquiring an additional 762,685 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Accolade by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 5,283,858 shares of the company’s stock valued at $55,903,000 after purchasing an additional 157,464 shares during the last quarter. Rock Springs Capital Management LP grew its position in Accolade by 3.3% during the third quarter. Rock Springs Capital Management LP now owns 2,913,000 shares of the company’s stock valued at $30,820,000 after buying an additional 93,000 shares during the period. Dimensional Fund Advisors LP increased its holdings in Accolade by 2.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,921,676 shares of the company’s stock valued at $23,083,000 after buying an additional 50,311 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its position in Accolade by 111.1% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,798,993 shares of the company’s stock worth $19,033,000 after acquiring an additional 946,970 shares during the period. 84.99% of the stock is currently owned by hedge funds and other institutional investors.

Accolade Stock Down 14.1 %

The company’s 50 day moving average price is $9.66 and its two-hundred day moving average price is $9.91. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.48. The firm has a market cap of $610.75 million, a PE ratio of -4.78 and a beta of 2.08.

Accolade (NASDAQ:ACCD) last announced its earnings results on Thursday, April 25th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. Accolade had a negative return on equity of 27.27% and a negative net margin of 31.59%. The company had revenue of $124.80 million for the quarter, compared to analysts’ expectations of $123.91 million. During the same period last year, the firm earned ($0.42) EPS. Accolade’s revenue for the quarter was up 26.1% compared to the same quarter last year. On average, equities research analysts expect that Accolade, Inc. will post -1.33 EPS for the current fiscal year.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.